SpringWorks Therapeutics Inc

NASDAQ:SWTX   3:59:54 PM EDT
60.05
+0.45 (+0.76%)
Products, Strategic Combinations, Regulatory

Springworks Therapeutics Announces Clinical Collaboration With Pfizer Inc To Evaluate Nirogacestat In Combination With Pf‐06863135 In Patients With Relapsed Or Refractory Multiple Myeloma

Published: 10/05/2020 11:05 GMT
SpringWorks Therapeutics, Inc. (SWTX) - Springworks Therapeutics Announces Clinical Collaboration With Pfizer Inc. to Evaluate Nirogacestat in Combination With Pf‐06863135 in Patients With Relapsed Or Refractory Multiple Myeloma.
Springworks Therapeutics - Pfizer and Co Will Also Form Joint Development Committee to Manage Clinical Study Which is Expected to Commence in H1 2021.
Springworks Therapeutics - Pfizer to Sponsor, Conduct Phase 1b/2 Study to Evaluate Safety, Tolerability & Prelim Efficacy of Nirogacestat Combination.
Springworks Therapeutics - Also Currently Conducting Global Phase 3 Clinical Trial to Evaluate Nirogacestat in Adults With Progressing Desmoid Tumors.